Crossmark

Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre, randomized and open-label controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-024-08364-7

Published Online: 2024-08-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Huan

Huang, Jie

Tao, Liyuan

Liu, Dongyang

Song, Chunli http://orcid.org/0000-0002-3690-9457
License Information

Text and Data Mining valid from 2024-08-13

Version of Record valid from 2024-08-13
More Information

Article History

Received: 10 December 2022

Accepted: 1 August 2024

First Online: 13 August 2024

Declarations

:

: This study protocol has been registered with ClinicalTrials.gov ID NCT05645289. This study protocol was reviewed and approved by Peking University Third Hospital Medical Science Research Ethics Committee on 16 August 2022 (M2022465, 2022.08.09, V2.0). Written informed consent will be obtained from all participants prior to performing trial-related procedures. Participants will have the right to withdraw at any time and for any reason without prejudice related to their future medical care.

: The authors declare that they consent for publication.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below